75 results about "Cancer development" patented technology

The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.

A method for inhibiting or preventing cancer development by the administration of fatty acid synthase (FAS) inhibitors. In particular, the present invention prohibits or delays the development of invasive cancer from pre-malignant (non-invasive) lesions that express FAS. Compositions containing FAS inhibitors also are provided, as well as methods for administering the FAS inhibitors and compositions to patients in need thereof.

A universal data-mining platform capable of analyzing mass spectrometry (MS) serum proteomic profiles and/or gene array data to produce biologically meaningful classification; i.e., group together biologically related specimens into clades. This platform utilizes the principles of phylogenetics, such as parsimony, to reveal susceptibility to cancer development (or other physiological or pathophysiological conditions), diagnosis and typing of cancer, identifying stages of cancer, as well as post-treatment evaluation. To place specimens into their corresponding clade(s), the invention utilizes two algorithms: a new data-mining parsing algorithm, and a publicly available phylogenetic algorithm (MIX). By outgroup comparison (i.e., using a normal set as the standard reference), the parsing algorithm identifies under and/or overexpressed gene values or in the case of sera, (i) novel or (ii) vanished MS peaks, and peaks signifying (iii) up or (iv) down regulated proteins, and scores the variations as either derived (do not exit in the outgroup set) or ancestral (exist in the outgroup set); the derived is given a score of “1”, and the ancestral a score of “0”—these are called the polarized values. Furthermore, the shared derived characters that it identifies are potential biomarkers for cancers and other conditions and their subclasses.

Transgenic, non-human animal model of cancer, methods of making such animals and methods of using such animals to screen test compounds are provided.

We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome “fingerprints”. We generated HLA-DRβ1*0101-restricted CD4⁺ T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4⁺ T cells are potential targets for cancer immunotherapy.

In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of Sodium-dependent Phosphate Transporter lsoform NaPi-3b protein (SLC34A2) with Proto- oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

The invention belongs to the fields of immunology, tumor microenvironment and tumor immnuotherapy and provides a DC-CIK cell and anti-PD-1 antibody composition which is used for preparing immune drugs for treating cancers or delaying cancer development. The invention provides a combined immune composition for treating cancers, and the composition is formed by an effective dose of DC-CIK cells and an anti-PD-1 antibody. According to the combined immune composition, the immunocompetence for killing the cancer cells in a patient body can be effectively enhanced, and a cancer clinic treatment effect can be improved or the cancer development can be delayed hopefully.

The disclosure herein relates to the novel finding that pattern recognition receptor activation is central to pancreatic cancer progression, and provides antagonists of pattern recognition receptors (PRRs), including the TLRs 4, 7, and 9, and the CLR dectin-1, for treatment and prevention of pancreatic cancer and pancreatic inflammation. The inventors have discovered that cancer development and progression can be prevented by pattern recognition receptor inhibition, a powerful finding with important clinical and therapeutic implications.

The invention relates to the graded expression level of SNAIL gene or its expression products, as a marker of the capacity of epithelial and mesenchymal tumours and/or cancers for disseminating to other tissues or organs. The invention further relates to a transgenic non-human mammal comprising in its genome a transgene that comprises a nucleic acid sequence encoding the SNAIL protein, and the use of SNAIL as a marker of epithelial and mesenchymal tumours and/or cancers as well as in DNA damage-based diseases In addition, the invention relates to the use of SNAIL as a therapeutic and diagnostic target for said pathologies.

The present invention provides a method capable of detecting a cancer and/or a carcinogenic risk, and a reagent for the detection thereof. The present invention also provides a method for screening for a pharmaceutical drug for reducing a carcinogenic risk and a pharmaceutical composition. Since cancer development closely correlates with alteration in gut microbiota, cancer development and/or a risk of cancer development are detected by detecting alteration in gut microbiota and a secondary bile acid produced by an intestinal bacterium. The present invention further provides a method for screening for a pharmaceutical drug with a gut microbiota as an index, and a pharmaceutical composition.